BPH Treatment Options: Quick Relief vs. Long-Term Durability

Managing benign prostatic hyperplasia (BPH)—which affects over 70% of men in their 60s—often comes down to a crucial tradeoff: rapid symptom relief versus long-term treatment durability.

While traditional surgeries like transurethral resection of the prostate (TURP) offer long-lasting relief, they carry a higher risk of side effects like retrograde ejaculation and incontinence. Modern minimally invasive BPH therapies—including Rezum water vapor, UroLift implants, and the Optilume drug-coated balloon—provide quick recovery times with minimal impact on sexual function. However, these approaches carry higher retreatment rates over time, ranging from ~4% for Rezum to nearly 14% for UroLift after five years.

For larger prostate volumes, therapies like Aquablation combine robotic precision with TURP-level symptom reduction, significantly lowering the risk of recurrent treatment. Meanwhile, newly cleared options like temporary prostate stents offer promising in-office solutions.

Selecting the right BPH treatment requires evaluating your unique prostate anatomy, volume, and lifestyle priorities alongside your urologist.

Sandburg, B. (2026, June 26). Prostate care: Quick relief vs retreatment. Medscape Medical News. https://www.medscape.com/viewarticle/prostate-care-quick-relief-vs-retreatment-2026a1000lsc